Ser289
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser289  -  DAPK1 (human)

Site Information
QALSRKAsAVNMEkF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 457379

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 , 4 , 5 , 6 , 7 , 8 , 9 ) , mutation of modification site ( 1 , 9 ) , phospho-antibody ( 1 , 9 ) , western blotting ( 1 )
Disease tissue studied:
HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , lung cancer ( 6 ) , non-small cell lung cancer ( 6 ) , non-small cell squamous cell lung carcinoma ( 6 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
p90RSK (human) ( 9 ) , RSK2 (human) ( 9 )
Kinases, in vitro:
DAPK1 (human) ( 1 )
Treatments:
phorbol_ester ( 1 , 9 ) , resveratrol ( 1 ) , U0126 ( 9 )

Downstream Regulation
Effects of modification on DAPK1:
activity, inhibited ( 9 ) , enzymatic activity, induced ( 1 )
Effects of modification on biological processes:
apoptosis, altered ( 9 ) , signaling pathway regulation ( 1 )

References 

1

Shiloh R, Bialik S, Kimchi A (2019) Ser289 phosphorylation activates both DAPK1 and DAPK2 but in response to different intracellular signaling pathways. Cell Cycle 18, 1169-1176
31116076   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

4

Rikova K (2012) CST Curation Set: 13915; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 1/treated; Disease: -; SILAC: -;
Curated Info

5

Mulhern D (2011) CST Curation Set: 12830; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

6

Rikova K (2011) CST Curation Set: 10892; Year: 2011; Biosample/Treatment: cell line, LOU-NH91/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

7

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

8

Possemato A (2009) CST Curation Set: 7390; Year: 2009; Biosample/Treatment: cell line, HepG2/-; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

9

Anjum R, et al. (2005) The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Curr Biol 15, 1762-7
16213824   Curated Info